Mayo Clinic Laboratories offers a robust menu of biomarker testing to assess liver disease related to nonalcoholic and alcoholic causes. These include FibroTest-ActiTest, a first-line screening assay that uses two diagnostic scores based on...
Learn more about how direct ethanol biomarker testing at Mayo Clinic Laboratories provides heightened sensitivity and specificity to accurately assess alcohol use and alcohol use disorder.
New tests launched in January - Insights
In January 2022, Mayo Clinic Laboratories announced twenty five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
FDA-approved test expands options for Alzheimer's disease - Insights
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for...
Communiqué Archives - Page 3 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
IDH assay facilitates timelier leukemia treatment: Rong He, M.D. - Insights
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.
Chromium and Cobalt - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' synovial fluid testing for patients with symptoms of failed hip arthroplasty. The Food and Drug Administration recommends testing for elevated chromium and cobalt, which can indicate...
Monoclonal Gammopathy Informative Cases - Insights
Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders.
PIK3CA assay guides treatment of progressing breast cancer - Insights
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
Myeloproliferative neoplasms - Insights
Learn about our reflexive molecular testing protocols that are designed to guide proper utilization of myeloproliferative neoplasms.